Abstract
The current guidelines recommend a dosage of prednisone of 60 mg/m2 body surface area per day (BSA PRED) for the initial therapy of nephrotic syndrome (NS). Alternatively, a dosage of 2 mg/kg body weight per day (W PRED) can be used. We hypothesized that the BSA PRED and W PRED are not equivalent and analyzed the differences between BSA PRED calculated with various formulas for body surface area (BSA), W PRED and the dose of prednisone prescribed for our patients. We performed a retrospective chart review of the patients at their initial presentation of NS. Thirty-three children were included, of median age 3.34 years at presentation. The W PRED was significantly lower than BSA PRED (P < 0.05), with a median W PRED:BSA PRED ratio of 0.85 [interquartile range (IQR) 0.8 to 0.9]. The difference between W PRED and BSA PRED decreased proportionally to patients’ weights up to 30 kg. No differences were noted between the various BSA formulas using both weight and height for the calculation of BSA. The Bland–Altman analysis showed a proportional error between W PRED and BSA PRED up to the average daily dose of 60 mg, with a mean bias of 0.86 (95% limits of agreement = 0.68 to 1.05). Ten out of the 33 patients (30%) were given a lower than recommended BSA PRED dose by more than 5 mg/day. In conclusion, the dosage of prednisone at 2 mg/kg per day versus 60 mg/m2 per day is not equivalent for patients with weights <30 kg and/or dose <60 mg/day.
Similar content being viewed by others
References
International Study of Kidney Disease in Children (1979) Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr 95:239–243
Arbeitsgemeinschaft für Pädiatrische Nephrologie (1988) Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Lancet 1:380–383
Melvin T, Bennett W (1991) Management of nephrotic syndrome in childhood. Drugs 42:30–51
Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152:357–361
Gauthier B, Trachtman H (1999) Pharmacological treatment of nephrotic syndrome. Drugs Today (Barc) 35:13–26
Filler G (2003) Treatment of nephrotic syndrome in children and controlled trials. Nephrol Dial Transplant 18 [Suppl 6]:vi75–vi78
Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M, West Japan Cooperative Study Group of Kidney Disease in Children (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155–1162
Hoyer PF, Brodehl J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151–1157
Ksiazek J, Wyszyńska T (1995) Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 84:889–893
Ekka BK, Bagga A, Srivastava RN (1997) Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 11:597–599
Bagga A, Hari P, Srivastava RN (1999) Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol 13:824–827
Indian Pediatric Nephrology Group, Indian Academy of Pediatrics (2008) Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45:203–214
Warshaw BL, Hymes LC (1989) Daily single-dose and daily reduced-dose prednisone therapy for children with the nephrotic syndrome. Pediatrics 83:694–699
Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S, Strife CF, Arbus G (2003) Long versus standard initial steroid therapy for children with the nephrotic syndrome. A report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 18:342–346
Hodson EM, Willis NS, Craig JC (2007) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (4):CD001533
Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098
Current JD (1998) A linear equation for estimating the body surface area in infants and children. Internet J Anesthesiol 2:2
Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93:62–66
DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871
Rose JQ, Yurchak AM, Jusko WJ (1981) Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389–417
Lack JA, Stuart-Taylor ME (1997) Calculation of drug dosage and body surface area of children. Br J Anaesth 78:601–605
Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S, Chemotherapy Standardisation group of the United Kingdom Children’s Cancer Study Group (2001) Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 85:23–28
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Feber, J., Al-Matrafi, J., Farhadi, E. et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome—is it equivalent?. Pediatr Nephrol 24, 1027–1031 (2009). https://doi.org/10.1007/s00467-008-1089-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-1089-2